Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China; Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China; Anhui Collaborative Innovation Centre of Anti-Inflammatory and Immune Medicine, Hefei, China; Center of Rheumatoid Arthritis of Anhui Medical University, Hefei, China.
Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China; Third Hospital Affiliated to Anhui Medical University, Hefei, China.
Life Sci. 2024 Feb 15;339:122450. doi: 10.1016/j.lfs.2024.122450. Epub 2024 Jan 21.
Acute kidney injury (AKI) is a clinical syndrome characterized by a sudden and continuous decline in renal function. The drug cisplatin is commonly used as chemotherapy for solid tumors, and cisplatin-induced acute kidney injury (CI-AKI), which is characterized by acute tubular necrosis and inflammation, frequently occurs in tumor patients. Renal tubular epithelial cells (RTECs) are severely damaged early in this process and play an important role in renal tubular injury and the recruitment of immune cells. Macrophages are the most common infiltrating immune cells in the kidney and have a significant impact on CI-AKI and subsequent repair. This article reviews the latest research progress on the effects of RTECs and macrophages on CI-AKI and their interactions in AKI to provide a direction for identifying therapeutic targets for treating AKI.
急性肾损伤（AKI）是一种以肾功能突然持续下降为特征的临床综合征。顺铂是一种常用于治疗实体瘤的化疗药物，顺铂诱导的急性肾损伤（CI-AKI）以急性肾小管坏死和炎症为特征，常发生在肿瘤患者中。在这个过程中，肾小管上皮细胞（RTEC）早期受到严重损伤，在肾小管损伤和免疫细胞募集中发挥重要作用。巨噬细胞是肾脏中最常见的浸润免疫细胞，对 CI-AKI 及其随后的修复有显著影响。本文综述了 RTEC 和巨噬细胞对 CI-AKI 的影响及其在 AKI 中的相互作用的最新研究进展，为寻找治疗 AKI 的治疗靶点提供了方向。
